skip to main content
Idioma:
Primo Search
Clear Search Box
Search in: Busca Geral
Busca Avançada
Busca por Índices

Uterin adenosarcoma: French Guidelines of the French Sarcoma Group and the Rare Gynecologic Tumor Group

Karabajakian, Andy ; Genestie, Catherine ; Meeus, Pierre ; Guyon, Frédéric ; Llacer Moscardo, Carmen ; Croce, Sabrina ; Taieb, Sophie ; Duffaud, Florence ; Pautier, Patricia ; Ray-Coquard, Isabelle ; Blay, Jean-Yves

Bulletin du cancer, 2023-07, Vol.110 (7-8), p.836 [Periódico revisado por pares]

France

Sem texto completo

Citações Citado por
  • Título:
    Uterin adenosarcoma: French Guidelines of the French Sarcoma Group and the Rare Gynecologic Tumor Group
  • Autor: Karabajakian, Andy ; Genestie, Catherine ; Meeus, Pierre ; Guyon, Frédéric ; Llacer Moscardo, Carmen ; Croce, Sabrina ; Taieb, Sophie ; Duffaud, Florence ; Pautier, Patricia ; Ray-Coquard, Isabelle ; Blay, Jean-Yves
  • Assuntos: Adenosarcoma - surgery ; Female ; Genital Neoplasms, Female - therapy ; Hormones ; Humans ; Neoplasm Recurrence, Local - therapy ; Uterine Neoplasms - surgery
  • É parte de: Bulletin du cancer, 2023-07, Vol.110 (7-8), p.836
  • Descrição: Uterine adenosarcoma is a very rare malignancy defined as a biphasic tumor composed of both benign epithelial component and a malignant sarcoma component. The stage of the disease is determined by the presence of myometrial invasion and the extent of extra-uterine disease. The most important histopronostic factors are the existence of a sarcomatous overgrowth defined by a sarcomatous contingent occupying more than 25 % of the volume of the tumor (directly correlated to the grade of the disease), the presence of a heterologous and/or a high-grade component. Stage I adenosarcomas without sarcomatous overgrowth have a good prognosis, with an overall 5-year survival of up to 80 %. In localized disease, complete surgical removal is recommended. The role of hormone therapy, chemotherapy and adjuvant radiotherapy is not established. If possible, relapses should be re-treated surgically, with the aim of achieving complete resection. In the advanced inoperable or metastatic setting, hormone therapy is an option for low-grade adenosarcomas with estrogen receptor (ER) and progesterone receptor (PR) overexpression. For high-grade tumors, the standard chemotherapies are doxorubicin-based combinations, although an integrated approach of surgery and medical treatment should also be considered in this setting.
  • Editor: France
  • Idioma: Francês
Links
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.